Last fall BioCryst ($BCRX) took a careful look at the interim data from a late-stage study of its flu drug peramivir i.v. and prepared to read the last rites for the program after years of federally-funded research work. The company gave up on enrolling more patients and said any further development with an eye to filing for an approval in the U.S. was "unlikely."
Months after the beleaguered BioCryst Pharmaceuticals ($BCRX) started reading the last rites for its long-running Phase III program for the flu drug peramivir i.v., citing a weak response and the need to add more patients to the study, the biotech has tried to cheer up its battered investors with the news that the therapy may not be completely dead after all.
After this latest setback, the company's chief medical officer says that it is "unlikely" that the biotech will continue development work needed for U.S. approval.
Shares of BioCryst Pharmaceuticals slid about eight percent on the news that it wants to expand the size of its late-stage study of its IV formulation of peramivir while altering the endpoint. The
Just days after federal regulators rushed through an emergency approval for the use of BioCryst's IV flu drug peramivir, the Alabama biotech says that it's shipped 10,000 courses of the treatment,
There's been a considerable amount of speculation about which of the new flu vaccine and antiviral technologies now in the clinic will benefit from the swine flu outbreak and the outcry it has
The U.S. government is handing BioCryst Pharmaceuticals (BCRX) more than $77 million to finish the late-stage testing of its promising anti-viral drug peramivir. The department of Health and Human
BioCryst Pharmaceuticals came out of the gate this morning touting new distribution deals for its closely-watched antiviral peramivir, but some analysts were doubtful that the developer had much new
With the world's first pandemic in more than four decades covering the globe, BioCryst took another step toward FDA approval for its flu therapy peramivir with the announcement that two late-stage
> Novartis has told Orion Corp.--which put out a press release--that Stalevo has produced positive data in a late-stage Parkinson's trial.